Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Somaxon To Put Silenor Phase III Program To Bed In December

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm's Q3 2007 filing timeframe puts it ahead of Neurocrine's resubmission plans for immediate-release indiplon.

You may also be interested in...



Somaxon Pushes Back Insomnia Drug Silenor NDA Filing To Q1 2008

FDA asks firm to submit findings of a 26-week mouse toxicity study along with NDA, Somaxon tells “The Pink Sheet” DAILY.

Somaxon Pushes Back Insomnia Drug Silenor NDA Filing To Q1 2008

FDA asks firm to submit findings of a 26-week mouse toxicity study along with NDA, Somaxon tells “The Pink Sheet” DAILY.

Vanda Moves Ahead With Development Of Iloperidone, VEC-162

Following an end-of-Phase II meeting with FDA, Vanda plans to initiate a Phase III study of VEC-162 in sleep disorders in third quarter.

Related Content

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel